E-viri
PDF
Recenzirano
Odprti dostop
-
Klaeschen, Anna Sophie; Wolf, Dominik; Brossart, Peter; Bieber, Thomas; Wenzel, Joerg
Experimental dermatology, August 2017, Letnik: 26, Številka: 8Journal Article
This study was stimulated by the clinical observation of a rapid response of a chilblain lupus patient to treatment with JAK1/2‐kinase inhibitor ruxolitinib. We investigated the in vivo expression of phospho‐JAK2 in CLE skin samples as well as the immunomodulatory in vitro effect of ruxolitinib in cultured immortalized keratinocytes and in a 3D human epidermis model (epiCS). Our results demonstrate that ruxolitinib significantly decreases the production of CLE‐typical cytokines (CXCL10, CXCL9, MxA) and might be a promising drug for future clinical studies in patients with CLE and related autoimmune skin diseases.
